4.7 Article

Early sepsis diagnosis via protein and miRNA biomarkers using a novel point-of-care photonic biosensor

Journal

ANALYTICA CHIMICA ACTA
Volume 1077, Issue -, Pages 232-242

Publisher

ELSEVIER
DOI: 10.1016/j.aca.2019.05.038

Keywords

Point-of-care; Label-free multiplexed biosensing; Nanoplasmonics; Sepsis; Protein and miRNA biomarkers; Microarray

Funding

  1. European Union's Horizon 2020 Research and Innovation program (RAIS Project) [644956]
  2. CERCA program / Generalitat de Catalunya
  3. Severo Ochoa program from Spanish MINECO [SEV-2017-0706]
  4. FEDER funds from the European Regional Development Funds program [FICTS-1420-27]
  5. SNSF [178438]
  6. Spanish Ministry of Economy and Competitiveness through the Severo Ochoa Programme for Centres of Excellence in RD [SEV-2015-0522]
  7. Spanish Ministry of Economy and Competitiveness through OPTO-SCREEN [TEC2016-75080-R]
  8. Fundacio Privada Cellex
  9. Generalitat de Catalunya through the CERCA program
  10. AGAUR [2017 SGR 1634]

Ask authors/readers for more resources

y Sepsis is a condition characterized by a severe stage of blood-infection often leading to tissue damage, organ failure and finally death. Fast diagnosis and identification of the sepsis stage (sepsis, severe sepsis or septic shock) is critical for the patient's evolution and could help in defining the most adequate treatment in order to reduce its mortality. The combined detection of several biomarkers in a timely, specific and simultaneous way could ensure a more accurate diagnosis. We have designed a new optical point-of-care (POC) device based on a phase-sensitive interferometric biosensor with a label-free microarray configuration for potential high-throughput evaluation of specific sepsis biomarkers. The sensor chip, which relies on the use of metallic nanostructures, provides versatility in terms of biofunctionalization, allowing the efficient immobilization of different kind of receptors such as antibodies or oligonucleotides. We have focused on two structurally different types of biomarkers: proteins, including C-reactive protein (CRP) and Interleukin 6 (IL6), and miRNAs, using miRNA-16 as an example. Limits of Detection (LoD) of 18 mu g mL(-1), 88 mu g mL(-1) and 1 mM (6 mu g mL(-1)) have been respectively obtained for CRP, IL6 and miRNA-16 in individual assays, with high accuracy and reproducibility. The multiplexing capabilities have also been assessed with the simultaneous analysis of both protein biomarkers. (C) 2019 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available